益生菌干预改善了药物诱导的肝损伤患者的胆固醇参数:现实世界的回顾性研究
Na Li1, Penghui Liu1, Jiwu Guo1
1The General Surgery Department, Lanzhou University Second Hospital, Lanzhou, China.
肠道微生物群干预显著改善了肝功能,并减少了药物诱导性肝损伤 (DILI) 患者的损伤严重程度. 这种疗法对DILI管理有前途,特别是在胆固醇症占主导地位的病例中.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 微生物组研究 微生物组研究
- 胃肠病学 胃肠病学
背景情况:
- 药物诱导性肝损伤 (DILI) 是一个重大的临床挑战.
- 人们越来越认识到肠道微生物群在肝脏健康和疾病中的作用.
- 准肠道微生物群可能为DILI提供新的治疗策略.
研究的目的:
- 研究肠道微生物群干预对DILI患者治疗结果的影响.
- 评估微生物向治疗在改善肝功能和减少损伤严重性的有效性.
主要方法:
- 对120名住院DILI患者的回顾性分析.
- 干预组 (接受肠道微生物群治疗) 与对照组之间的比较.
- 统计分析包括曼 - 惠特尼U测试,奇平方测试和后勤回归.
主要成果:
- 与对照组相比,干预组的肝酶 (GGT,ALP,TBIL,DBIL,IBIL) 的改善显著更大 (p < 0.01).
- 肠道微生物群干预导致DILI严重程度和风险显著降低 (OR = 0.018,p < 0.01).
- 治疗后的DILI等级与治疗方案和肝酶有显著的相关性.
结论:
- 益生菌干预显著改善了与胆固醇酶相关的参数,并减少了DILI的严重程度.
- 针对微生物群的治疗是一种有前途的辅助策略,用于DILI,特别是胆固醇的主要DILI.
- 这项研究提供了现实世界的临床证据,支持DILI管理中的肠道微生物群调节.
更多相关视频
04:53A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
Published on: September 20, 2019
07:15An In Vitro Batch-culture Model to Estimate the Effects of Interventional Regimens on Human Fecal Microbiota
Published on: July 31, 2019
相关概念视频
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic Pancreatitis II: Collaborative Care
Assessment:
Bioavailability Study Design: Healthy Subjects Versus Patients
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
